FOR IMMEDIATE RELEASE                                          

Annette Fribourg
Vice President
Correlogic Systems, Inc.
tel. 301/214-4030
afribourg@correlogic.com

Development of Correlogic’s Prostate Cancer Blood Tests to Move Forward through Research Collaboration with the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine

Two Thousand Patient Samples To Be Examined in Concurrent Studies

BETHESDA, MD – May 3, 2005 -- Correlogic Systems, Inc. today announces a research collaboration with the Uniformed Services University of the Health Sciences (USU) and the Henry M. Jackson Foundation for the Advancement of Military Medicine (Foundation).  Under the agreement, USU’s Center for Prostate Disease Research (CPDR) and the Foundation will collaborate with Correlogic on a study of up to 2,000 men with specified prostate cancer conditions in order to further expand research on the use of Correlogic’s protein pattern recognition approach and technology in prostate cancer. 

This agreement provides for two concurrent studies. The first study will expand Correlogic’s research on the use of its “hidden patterns” approach and ProteomeDx^® pattern recognition technology to the detection of prostate cancer.  The goal is to develop a more effective blood test for the detection of prostate cancer. 

The current prostate specific antigen (PSA) test is most accurate for men whose PSA levels are outside the 2.5-10 ng/ml range.  Men whose PSA levels are within the 2.5-10 ng/ml “gray zone” frequently undergo prostate biopsies, though approximately 75 percent are ultimately determined not to have prostate cancer.  For these men a blood test that is a more accurate indicator could reduce the need for painful, invasive and costly procedures. 

Correlogic’s research demonstrating the effectiveness of its pattern recognition approach and technology in detecting prostate cancer has been published in the peer-reviewed journals, Journal of the National Cancer Institute and Journal of Urology.

The second study will center on men undergoing radical prostatectomies to determine whether Correlogic’s approach and technology can be extended to distinguish between indolent and aggressive prostate cancer.  Because most cases of prostate cancer are slow-growing, and life quality effects of prostate cancer treatment can be a concern, distinguishing whether a prostate cancer is aggressive is highly important in determining the extent or necessity of treatment.  Currently there is no effective prospective test for determining the aggressiveness of prostate cancer in most men.

 “The determination of aggressive versus indolent prostate cancer means the difference between life and death, and necessary versus unnecessary treatment,” said Peter J. Levine, President and CEO of Correlogic Systems.

The American Cancer Society estimates over 232,000 men in the U.S. will be diagnosed with prostate cancer in 2005.  About 30,350 men will die of prostate cancer this year.  Prostate cancer is the most common non-skin cancer among men in the U.S., and the second leading cause of cancer deaths in men.  One in six men will be diagnosed with prostate cancer during their lifetimes. 

“The goal of this powerful combination of the technology and research capacity of Correlogic Systems, and the CPDR is improved diagnosis and treatment of prostate cancer,” said Dr. Shiv Srivastava, Scientific Director of the CPDR.  “Because of the prevalence of prostate cancer, a prognostic blood test would be an important development to all men.”

About Correlogic Systems, Inc.

Correlogic Systems, Inc. is a Bethesda, Maryland-based clinical proteomics company that has developed proprietary technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery.  The technology’s first application has been in the field of proteomics – the study of human proteins – with concentration on the early detection of prostate, ovarian, breast and other cancers.  Correlogic is a pioneer in the development and application of pattern recognition in disease detection.  Correlogic has entered into licensing agreements with Laboratory Corporation of America and Quest Diagnostics, Inc. for the North American market development and commercialization of a diagnostic test applying Correlogic’s technology to ovarian cancer.  The company’s OvaCheck^™ blood test for the early detection of ovarian cancer is undergoing the final stages of its extensive validation process. 

Visit Correlogic Systems at www.correlogic.com.

About the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, and the Center for Prostate Disease Research

USU is a fully accredited federal school of medicine operated by the U.S. Department of Defense. USU is located in Bethesda, MD.  The Foundation is a private not-for-profit organization authorized by Congress to support medical education and research at USU and throughout the military medical community.  The Foundation is located in Rockville, MD.  The CPDR is a program of the Department of Surgery at USU and the Foundation.

Cautionary Statement:

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances.  Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.